An overview of November’s 10 most-read Medtech Insight articles on topics related to research and development of new medical technology.

Koa Accel CEO Francis Duhay tells Medtech Insight what his company looks for when choosing medtech ideas to support and how his experience as a physician and inventor informs his investment strategy.

Koa Accel CEO Francis Duhay outlines his company’s plans to take some of the risk out of investing in medical device start-ups by supporting inventors with functional expertise. The Irvine, CA-based medical device accelerator is focused on start-ups that will either “fail fast” or earn a 510(k) clearance within 18 months.

November’s approvals include the US FDA approval of Medtronic’s In.Pact AV paclitaxel-coated balloon, for the treatment of arteriovenous access in patients with end-stage renal disease, and a CE mark that expands the indication for Edwards’ Sapien 3 TAVR device to include patients at low-risk during surgery.

In this week's Medtech Insight podcast, deputy editor Reed Miller discusses clinical trial news from the annual American Heart Association (AHA) meeting, and senior reporter Catherine Longworth highlights goings-on at the Jefferies Healthcare Conference in London.

The results from the PROMISE I feasibility study give LimFlow confidence that the PROMISE II pivotal trial will prove that the LimFlow percutaneous deep vein arterialization system is a safe and effective alternative to amputation for patients with critical limb ischemia.